<DOC>
	<DOC>NCT02660580</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy, safety and immunogenicity of MSB11022 and HumiraÂ® in adult subjects with moderate to severe chronic plaque type psoriasis.</brief_summary>
	<brief_title>MSB11022 in Moderate to Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Male or female subjects greater than or equal to (&gt;=) 18 years old with a clinical diagnosis of stable moderate to severe plaque psoriasis (defined by Psoriasis Area and Severity Index [PASI] score &gt;=12, Physician Global Assessment [PGA] score &gt;=3, and &gt;=10% of body surface area affected at Screening and Baseline [Day 1 of Week 1]) who have a history of receipt of or are candidates for systemic therapy or phototherapy for active plaquetype psoriasis despite topical therapy Subjects must not have received more than 1 biologic therapy Other protocoldefined inclusion criteria could apply Subjects will be excluded if they have erythrodermic, pustular, guttate, or medicationinduced forms of psoriasis or other active skin diseases/infections that may interfere with the evaluation of plaque psoriasis Subjects must not have received adalimumab or an investigational or licensed biosimilar of adalimumab; topical therapies for the treatment of psoriasis or ultraviolet B phototherapy within 2 weeks of investigational medicinal product (IMP) administration or plan to take such treatment during the trial; or psoralen combined with ultraviolet A phototherapy or nonbiological systemic therapies for psoriasis within 4 weeks prior to IMP administration Subjects will also be excluded if they have a history of an ongoing, chronic, or recurrent infectious disease (except for latent tuberculosis [TB]); history of active TB; or a history of hypersensitivity to any component of the IMP formulation, comparable drugs, or latex Other protocoldefined exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Adalimumab</keyword>
	<keyword>MSB11022</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Phase III</keyword>
</DOC>